

Global Markets Review

After a relief rally from mid-July to mid-August, global equity markets gave up all gains and finished the third quarter with negative returns. Both equity and bond markets continued to suffer from decade-high inflation and central banks' aggressive monetary tightening. Volatility remained high across all major asset classes, while the recessionary risk has been rising as well. For the three-month period ended September 30, 2022, the MSCI World Index fell by 6.1%. Consumer Discretionary was the only sector that registered positive returns (+0.3%), while Communication Services was the bottom-performing sector (-12.9%). In North America, the S&P 500 dropped by 4.9% with Consumer Discretionary also the best-performing sector. The S&P/TSX Composite lost 1.4%, boosted by Industrials. In Europe, the STOXX 600 was down 4.2% for the third quarter of this year. Major European indices also registered negative returns. Italy's FTSE MIB was the best-performing index (-2.5%). France CAC 40 and the U.K. FTSE 100 were down by 2.5% and 2.8%, respectively. Switzerland, Germany, and Spain lost 4.3%, 5.2%, and 8.3%, respectively.

Inflation has remained stubbornly high, which continues to challenge global economic growth. Energy prices have come down from the peak. Meanwhile, global supply chain disruptions continued easing. However, ripples from geopolitical tensions between Russia and Ukraine still linger. While a variety of key economic measures remained sound during the third quarter, deterioration in other data suggested an economic slowdown. August CPI pointed at 8.3%, a further deceleration from the peak in June, but this elevated inflation level would be unlikely to slow the pace of further aggressive monetary tightening. Rising inflation is eroding real wage growth, while unemployment rates continue to see sequential decline to pre-pandemic lows. Manufacturing PMI entered September at 50.9, which has largely trended down since its peak in March 2021. Bond market also sold off during the quarter. The U.S. Treasury market kept rising sharply in response to the inflation overshoot and monetary tightening, while the 2-year and 10-year Treasury spread remained in below-zero territory during the quarter. During the last few days of September, the newly formed U.K. government announced a fiscal package including a tax cut program that raised concerns of adding inflationary pressure to the economy. As a result, the budgetary announcement accelerated the market sell-off, sending GBP to an all-time low versus USD and the gilt yields surged accordingly. With most equity markets falling in Q3, Consumer Discretionary and Consumer Staples showed relative resilience thanks to strong consumer spending and still-low unemployment. Meanwhile, Energy stocks were boosted by solid Q2 results and strength in natural gas prices but were offset by weak oil prices during the quarter. Rate-sensitive sectors such as Real Estate generally underperformed amid the high interest rate environment.

Central banks in developed economies continued to deliver more hawkish stances of their monetary policy to combat inflationary risks. This quarter witnessed two consecutive 75-basis-point interest rate hikes—at the July and September Federal Open Market Committee ("FOMC") meetings—to the 3.00%-3.25% range. As the Fed reaffirmed its commitment to fighting inflation, the Fed funds futures market is pricing in another 140 basis points of tightening by year-end. This includes another two possible 0.75% hikes at both November and December meetings. Along with rate increases, the Committee also confirmed the full speed of balance sheet reduction at a pace of \$95 billion a month starting from September.

The Bank of Canada (BoC) delivered even more aggressive policy stances to tame inflation by raising its policy rate by 100 at the July meeting and 75 basis points at the September meeting. This sent Canada's overnight policy rate to 3.25%, bringing the cumulative hikes so far this year to 300 basis points, the fastest tightening pace since the mid-1990s. The statement communicated that "the policy rate will need to rise further". Higher interest rates will test Canadian households' ability to service their debts, as the housing market extended its cooldown during the third quarter.

The European Central Bank (ECB) started raising its benchmark interest rate during the quarter: 50 basis points in July, followed by 75 basis points in September. With the current benchmark interest rate at 1.25%, the ECB President Lagarde signaled that policy rates remain far below levels that ensure the return of 2% inflation. Given a deteriorating inflation picture in Europe, including rising wage growth and hefty energy prices, further rate hikes over the next several meetings should be expected to slow demand and curtail persistent inflationary pressure. Meanwhile, the Bank of England (BoE) voted to lift the policy rate by two consecutive 50 basis points hikes in August and September to 2.25%. However, the newly announced fiscal measure including a large amount of tax cuts drew global criticism, leading to a historic U.K. gilt and British pound sell-off. The BoE was forced to postpone the planned commencement of its gilt selling and begin temporary purchases of long-dated bonds in order to calm the market turbulence. Rating agencies Fitch and Standard & Poor's downgraded the outlook for the country's credit rating to reflect their lower confidence in the

U.K. financial market and the policy framework.

Visibility on inflation outlook is low. Some evidence suggests that components of CPI have shown signs of decline in the U.S. at the end of Q3. Food, housing, and transportation account for the largest portion of the recent CPI spike. Lower oil prices during the three-month period have pulled transportation costs lower. Falling grain prices from the peak should also bode well for a cooldown in food CPI component. However, Shelter inflation could remain higher and longer, as rent increases have been accelerating, especially on existing leases. In Europe, energy costs continued to be the top contributor to inflation. Nord Stream 1, whose gas supply capacity accounts for over 10% of European demand and over 50% of Germany's demand, was shut down for maintenance in July. It came onstream temporarily before Russia closed it again after several leaks were found. This put further pressure on the power generator. Countries such as Spain and Portugal were forced to cut VAT rate on electricity bills to tackle soaring energy prices. In short, inflationary pressure and associated geopolitical tensions are more problematic in Europe than North America.

Looking forward to the rest of 2022, the global economic slowdown should persist, and broad markets should continue to experience high volatility until a less-aggressive Fed pivot occurs. There are early signs of peak inflation, but this is not sufficient to stop global monetary tightening. Rising inflation has weighed on corporate margins and earnings growth. With still-high inflation, aggressive monetary tightening, and unresolved geopolitical tensions, we expect a further multiple compression across all sectors after the Q3 earnings season, but valuations of some companies are at levels that are historically attractive. Therefore, in response to the ongoing market turbulence, we are positioning our portfolios tilted towards more defensive names. We continue to favor high quality companies that demonstrate low sensitivity to rate hike cycle, sustainable earnings growth, and reasonable valuations. Regarding country exposure, we still favor U.S. and Canada over Europe, with mounting risks for European households and business tied to more severe inflationary pressure and geopolitical tensions. To take advantage of market volatility and cushion against further market decline, we have also increased our call options overwrite levels.

Healthcare Sector Review & Outlook

We continue to believe that healthcare offers an attractive risk/reward opportunity. Demand for healthcare services continues to increase, with a growing and aging population enjoying longer lifespans. In addition, continued innovation in the sector drives the introduction of new treatments for more complex diseases and expanding market opportunities for healthcare companies. We believe the healthcare sector provides both stable dividend and defensive characteristics. Many large cap healthcare stocks generate durable cash flow, due to their diverse product offerings, and can maintain pricing power and pass-through costs in inflationary environments. While recessionary pressures can be a headwind, we note that the healthcare sector performs consistently well both heading into a recession and following a recession. In the last 5 recessions since 1981, Healthcare had a median return of 14% relative to the S&P 500 12 months after recessions starts, which makes it the second-best performing sector.

The Inflation reduction Act which was passed and signed into law during Q3, lifts the uncertainty of drug-price reform to some extent. However, there is caution as to how some Medicare negotiation provisions will be interpreted and implemented. The bill calls for negotiated pricing for Part D drugs, to go into effect starting in 2026 in a phased approach, where the government will select from a list of 50 drugs. There is a significant amount of focus on the types of drugs that may be exempt from negotiations or are referenced specifically in the text, including: orphan drugs, new formulations, vaccines, plasma-derived therapy, and small biotech drugs. Companies with the most exposure are those where negotiation provisions pull forward losses of exclusivity for products that have significant exposure to Medicare based payments for revenue. Generic manufacturers may find the new law creates a price barrier to entry for certain treatments depending on government price-setting levels.

Medical costs are projected to increase 10% in 2023 (According to Bloomberg 7/7/2022). This is attributed to inflation in healthcare delivery (increase labour cost, rising logistics cost), medical utilization recovery and return of investments that were deferred during the pandemic. We note that during the pandemic health insurers benefited greatly from lower medical and surgical utilization. However, we believe this trend could reverse given the return of deferred care during the pandemic with arguably sicker patients from delay in treatment because of the pandemic. Industry commentary suggests that premium increases would likely not be enough to offset the increase in medical costs given the potential the recessionary environment (negative enrollment).

Overall, we believe healthcare is an attractively valued defensive sector that exhibits resiliency in the face inflationary and recessionary headwinds. We note that the pharma and biotech subsectors have one of the most stable and least volatile dividend yield profiles compared to other dividend paying industries. We believe stocks in our portfolio are well positioned in their respective end markets, driving growth and durable cash flow. Our active management approach allows us to capture factor rotations given the dynamic macro backdrop.

Portfolio Review

Brompton Global Healthcare Income & Growth ETF (the "Fund") was down 8.6% in Q3 2022 versus the MSCI World Health Care Index which was

down 6.7%.

The Fund's overweight position in healthcare distributors contributed to performance which was ahead of the benchmark. Top performers include McKesson which was up 4.3%.

The Fund's underweight position in the biotechnology subsector detracted from performance which lagged the benchmark. Our holdings in Abbvie and Amgen were down 6% and 8.7% respectively.

A market weight exposure to healthcare equipment detracted from performance which lagged the benchmark. Top performers include Dexcom (up 20.5%), IDEXX (up 13%) and Intuitive Surgical (up 9.2%).

The Fund's underweight position in healthcare facilities contributed to performance which was ahead of the benchmark. Our only holding in HCA Healthcare was up 18.2%.

In Life Sciences, the Fund was slightly overweight with performance lagging benchmark holdings. Our top performer was Danaher which was up 2%.

The Fund was overweight the pharmaceuticals subsector with performance slightly lagging the benchmark. Our holdings on average were down 12% versus the benchmark which was down 9.3%.

The Fund's overweight position in managed care detracted from performance which lagged the benchmark. Our top performer was United Health which was down 1.4%.

Laura Lau, CIO

Michael D. Clare, SVP & SPM

Annual Compound Returns ¹	YTD	1-YR	3-YR	5-YR	Since Inception ²	Since Inception ³
Brompton Global Healthcare Income & Growth ETF (CAD Hedged)	(23.7%)	(15.4%)	2.7%	4.7%	4.7%	-
Brompton Global Healthcare Income & Growth ETF (USD)	(24.1%)	(15.8%)	3.2%	-	-	2.9%

⁽¹⁾ Returns are for the periods ended September 30, 2022 and are unaudited. The table shows the ETF's compound return for each period indicated. Past performance does not necessarily indicate how the ETF will perform in the future. The information shown is based on Net Asset Value per unit and assumes that distributions made by the ETF on its units in the period shown were reinvested at Net Asset Value per unit in additional units of the ETF.

⁽²⁾ Inception Date September 24, 2015.

⁽³⁾ Inception Date August 8, 2019.

This document is for information purposes only and does not constitute an offer to sell or a solicitation to buy the securities referred to herein. The opinions contained in this report are solely those of Brompton Funds Limited ("BFL") and are subject to change without notice. BFL makes every effort to ensure that the information has been derived from sources believed to be reliable and accurate. However, BFL assumes no responsibility for any losses or damages, whether direct or indirect which arise from the use of this information. BFL is under no obligation to update the information contained herein. The information should not be regarded as a substitute for the exercise of your own judgment. Please read the prospectus before investing.

Commissions, trailing commissions, management fees and expenses all may be associated with exchange-traded fund investments. Please read the prospectus before investing. The indicated rates of return are the historical annual compounded total returns including changes in unit value and reinvestment of all distributions and do not take into account sales, redemption, distribution or optional charges or income taxes payable by any securityholder that would have reduced returns. Exchange-traded funds are not guaranteed, their values change frequently and past performance may not be repeated.

Certain statements contained in this document constitute forward-looking information within the meaning of Canadian securities laws. Forward-looking information may relate to matters disclosed in this document and to other matters identified in public filings relating to the Fund, to the future outlook of the Fund and anticipated events or results and may include statements regarding the future financial performance of the Fund. In some cases, forward-looking information can be identified by terms such as "may", "will", "should", "expect", "plan", "anticipate", "believe", "intend", "estimate", "predict", "potential", "continue" or other similar expressions concerning matters that are not historical facts. Actual results may vary from such forward-looking information. Investors should not place undue reliance on forward-looking statements. These forward-looking statements are made as of the date hereof and we assume no obligation to update or revise them to reflect new events or circumstances.

Investor Relations

PHONE 416.642.6000
TOLL FREE 1.866.642.6001
FAX 416.642.6001
EMAIL info@bromptongroup.com

Website

www.bromptongroup.com

Address

Bay Wellington Tower,
Brookfield Place
181 Bay Street
Suite 2930, Box 793
Toronto, Ontario M5J 2T3